Roivant Sciences Ltd. - 02 Aug 2021 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: 10%+ Owner
Issuer ticker: IMVT
Reported as of: 02 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Aug 2021, 21:46:46 UTC
Next SEC filing: 20 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Marianne Romeo Dinsmore, as Authorized Signatory

Key filing fact

Roivant Sciences Ltd. filed Form 4 for Immunovant, Inc. (IMVT) on 02 Aug 2021.

Key facts

This page summarizes Roivant Sciences Ltd.'s Form 4 filing for Immunovant, Inc. (IMVT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Aug 2021, 21:46.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock, $0.0001 par value per share

Other

Transaction value
Shares: +17,021,276
Change %: +30%
Price
Shares after: 73,388,664
Date: 02 Aug 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On August 2, 2021, Roivant and Immunovant, Inc. ("Immunovant") entered into a Share Purchase Agreement pursuant to which Roivant purchased 17,021,276 shares of Immunovant's common stock for an aggregate purchase price of $200,000,000, in cash, representing a per share price of $11.75.